Aswyn

Over Aswyn

Aswyn is a mission-driven executive advisory brand supporting founders, investors, and leadership teams in building scalable, resilient, and future-proof industrial organizations.

With more than 25 years of experience at COO / CTO / CEO level, Aswyn operates at the intersection of strategy, technology, and operations within highly regulated environments, including life sciences, pharmaceuticals, medical devices, chemicals, food, and high-tech manufacturing.

As a trusted sparring partner to CEOs and investors, Aswyn supports:

Strategic direction, scale-up execution, and CapEx decision-making

Translation of growth ambition into robust technical and operational roadmaps

Sustainable value creation with a clear focus on speed-to-market and industrial readiness

Aswyn delivers impact by:

Stabilizing and scaling complex production environments from scale-up to industrial maturity

Driving market-focused and strategic innovation with measurable business outcomes

Leading multidisciplinary teams across Operations, Engineering, Quality, R&D, and Commercial

Implementing data-driven Lean and Operational Excellence to improve OEE, capacity, OTIF, cost, and transparency

Designing and realizing new production and laboratory facilities

Implementing and operating within ISO 13485, ISO 14001, ISO 9001 and SHE frameworks

Aswyn combines strategic clarity with a hands-on, pragmatic execution style and a strong “can-do” mindset. Through visible leadership, coaching, and clear performance management, Aswyn builds cultures of trust, accountability, and operational excellence.

Aswyn is engaged when industrial complexity, growth pressure, and strategic ambition converge — and execution must deliver

Trefwoorden

• Chemicals
• Commercial Driven
• General Management
• High-Tech
• Industry
• Innovation
• Medical Devices
• Operational Excellence
• Team Growth

Adres

• Hoofdkantoor

  Engelse Schans 127137SE LieveldeGelderland, Nederland

Team per functiegebied

Gebaseerd op 1 openbare functieprofielen, stand van 3 september 2026.

• Executive / C-Suite1